Uncategorized
Revitalizing Cancer Therapy: UK Biotech Acquires Kyowa Kirin’s Former Drug for Epstein-Barr-Related Diseases
UK Biotech, Kyowa Kirin, cancer drug, Epstein-Barr virus, EBV-driven diseases, drug acquisition, therapy revival.
Merck KGaA Evades Legal Action Following DOJ Collaboration on China Export Investigation
Merck KGaA, DOJ, China, export scheme, cooperation, investigation, prosecution avoidance
Cytokinetics’ Royalty Agreement Dampens Merger and Acquisition Hopes, Say Investors
Cytokinetics, Merger and Acquisition (M&A), Royalty Agreement, Investors, Biotech Industry
RNA Startup ReNAgade Acquired by Competitor Following Mega-Round Funding
ReNAgade, RNA, startup, acquisition, competitor, mega-round funding, launch
Pharmaceutical Companies Prevail in 340B Case as Appeals Court Upholds Discount Restrictions
340B program, drugmakers, discounts, Appeals Court, ruling, healthcare, pharmaceuticals, hospitals, clinics.
Palisade Biotechnology’s Novel Ulcerative Colitis Treatment Shows Promising Results in Preclinical Studies
Palisade Biotechnology, ulcerative colitis, preclinical studies, nontoxic, mice, dogs, drug development, inflammatory bowel disease, treatment, prevention, symptoms
Evotec Discontinues Gene Therapy Operations, Shuts Down Austria Facility
Evotec, gene therapy, Austria, facility closure, strategic decision, business operations, research and development, biotechnology
Crinetics’s Atumelnant Shows Promising Early Results in Congenital Adrenal Hyperplasia Treatment
Crinetics, Atumelnant, congenital adrenal hyperplasia, early data, treatment, clinical trial, cortisol, androgens, ACTH, adrenal glands.
Revolutionary Oral Treatment for Retinal Disease Shows Promising Results in Phase II Trials
Retinal disease, oral treatment, Phase II trials, revolutionary, promising results, Rezolutes.
Sen. Wyden Scrutinizes Pfizer’s Tax Rate Amidst Ongoing Investigation
Sen. Wyden, Pfizer, tax rate, investigation, corporate taxation, tax avoidance, pharmaceutical industry, financial transparency